Biotech

Biotech Investing

  Denis Corin, chief executive of Q BioMed Inc. (OTCQB:QBIO) ) tells Proactive’s Andrew Scott their objective is to find innovative, under-valued and under-appreciated biotech assets out in the pharma world and bring them in-house through licensing and option agreements. ”[We’re] agnostic in terms of exit …. as long as there’s a significant return for shareholders”, …

 
Denis Corin, chief executive of Q BioMed Inc. (OTCQB:QBIO) ) tells Proactive’s Andrew Scott their objective is to find innovative, under-valued and under-appreciated biotech assets out in the pharma world and bring them in-house through licensing and option agreements.
”[We’re] agnostic in terms of exit …. as long as there’s a significant return for shareholders”, Corin says.

Source: www.proactiveinvestors.com

MARKETS

Markets
TSX20485.66-39.79
TSXV599.20+0.02
DOW34429.88+34.87
S&P 5004071.70-4.87
NASD11461.50-20.95
ASX7301.50-52.90

COMMODITIES

Commodities
Gold1798.03+0.31
Silver23.16+0.01
Copper3.85+0.04
Palladium1903.84+9.31
Platinum1020.00+2.01
Oil80.34-0.88
Heating Oil3.18-0.09
Natural Gas6.22-0.52

DOWNLOAD FREE REPORTS

×